Compare AdaptHealth Corp (AHCO) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AdaptHealth Corp vs Levi Strauss & Co. — how do they compare? AdaptHealth Corp trades at $10.02 (market cap $1.38B), while Levi Strauss & Co. trades at $24.15 (market cap $9.48B). The key difference: Levi Strauss & Co. is far larger — about 6.9× AdaptHealth Corp's market cap, and Levi Strauss & Co. pays a 2.27% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | LEVI | |
|---|---|---|
Market Cap | $1.38B | $9.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $13.38 | $24.83 |
52-Week Low | $8.68 | $17.92 |
Enterprise Value | $3.33B | $10.99B |
Dividend Yield | — | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
Levi Strauss (LEVI) trades at $24.66, up 1.02% with bullish technical indicators and strong earnings momentum after three consecutive quarterly beats. The company demonstrates robust profitability with a 61.69% gross margin and 9.52% net margin, supported by a $29.00 analyst consensus price target representing 17.6% upside. Recent news highlights Q2 2026 earnings anticipation and strategic focus on women's apparel expansion.
Outlook remains positive with earnings growth and dividend stability, though risks include inflationary pressures and competitive retail dynamics. The stock's current valuation at 18.15x P/E appears reasonable given 29.19% ROE, but investors should monitor Q2 results on July 8 for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AdaptHealth Corp
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
